ACON INJECTABLE INVESTORS I, L.P.
Status: Approved investmentWhy disclosure?
FMO is committed to making publicly available relevant investment information that informs stakeholders and enables them to engage directly with FMO on its investments which, in turn, enhances our investment decisions, the design and implementation of projects and policies, and strengthens development outcomes. Learn more
In case of questions
In case of questions, please contact us at disclosure@fmo.nl
Disclaimer
The information as disclosed is indicative and provided on an "as-is/as available" basis for general informational purposes only and should not be construed as financial, legal or investment advice, nor as a commitment or an offer to arrange or provide any financing. The final decision to provide financing is subject to the terms and conditions of FMO in its sole and absolute discretion. When providing links to other sites, FMO bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. The information on proposed investment for high-risk investments is made available in the language relevant to the country or region where the bulk of operations take place. Translations of any information into languages other than English are intended as a convenience for local stakeholders. In case of any discrepancy, the information provided in English will prevail.
Who is our customer
FMO’s investment in ACON Injectable Investors I, L.P. is used for further investment into Vitalis Group. Established in 1999, Vitalis Group is a leading manufacturer and distributor of generic injectable pharmaceuticals with production facilities in Colombia and Mexico, and sales to more than 20 countries, primarily in Latin America. The Group’s products are mainly used in surgical theaters, emergency rooms and intensive care units, and cover multiple therapeutic areas such as antibiotics, anesthesia, gastroenterology, oncology, and cardiology, among others.
What is our funding objective?
FMO's investment will be used to acquire the companies that comprise Vitalis Group, and to support its growth plans in order to contribute to the stability, growth and innovation of the domestic health care systems in Colombia and Mexico.
Why do we fund this investment?
This investment supports the deepening of local production capacity in Colombia and Mexico, and sales of essential medicines into Latin America, contributing to SDG3 (good health). Vitalis Group currently provides skilled labor opportunities to more than 1200 staff and is expected to add another 150 jobs over the next 5 years, in line with FMO’s aim to contribute to SDG8 (decent work and economic growth). Two thirds of the workforce are female employees, supporting SDG5 (gender equality).
What is the Environmental and Social categorization rationale?
The E&S category is B+
- Region
- Latin America & The Caribbean
- Country
- Latin America & The Caribbean
- Sector
- Infrastructure, Manufacturing and Services
- Effective date
- 5/17/2021
- Total FMO financing
- USD 19.68 MLN
- Funding
- FMO NV
-
Risk categorization on environmental and social impacts, A = high risk, B+ = medium high risk, B = medium risk, C = low risk
Environmental & Social Category
(A, B+, B or C) - B+